{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This open-label, single-arm, phase 2 trial conducted at 5 transplant centers"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 1,
        "evidence": "evaluated the ability of imlifidase to create a negative crossmatch test within 24 h"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "evaluated the ability of imlifidase to create a negative crossmatch test within 24 h"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 3,
        "evidence": "This open-label, single-arm, phase 2 trial"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "89.5% demonstrated conversion of baseline positive crossmatch to negative within 24 h after imlifidase treatment"
      },
      "Harms": {
        "score": 1,
        "evidence": "Seven adverse events in 6 patients were classified as possibly or probably related to treatment and were mild-moderate in severity"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 10,
    "max_score": 25
  },
  "model": "gpt-4o"
}